COMPANY PROFILE · /converge-bio
C
Converge Bio
Generative AI platform accelerating drug discovery and development by automating target identification, antibody design, and protein optimization. Works across oncology, autoimmune, and neurodegenerative research.
Fresh · 3d ago
Latest valuation
—
Annual Recurring Revenue
—
Headcount
34 employees
Funding total
$30M
OVERVIEW
Raised $25M Series A in Jan 2026 (Bessemer-led, backed by OpenAI, Meta, Wiz executives). Works with 12+ pharma companies on 40+ drug programs. Received $2.5M Bill & Melinda Gates Foundation grant.
Status
active
Tier
master-list
Profitability
Not disclosed; cash-efficient model
Pricing
enterprise
FUNDING HISTORY · 0
No funding rounds on file.
PRODUCTS · 0
No products catalogued yet. Press Refresh above to ask the research agent.
TEAM · 0 key people
No people linked.
SOURCES · 0 cited
No citations stored yet. Run the research agent to attach per-claim sources.